A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies
A Multi-Center Study of Multiple CAR T Cell Therapy for CD7-positive Hematological Malignancies is a PHASE1 clinical asset sponsored by Shenzhen Geno-Immune Medical Institute in T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma. SEO and diligence focus: CD7-specific CAR gene-engineered T cells, endpoint relevance, enrollment feasibility, competitive positioning, readout timing and IP durability.
Indication: T-cell Acute Lymphoblastic Leukemia
Modality: cell therapy
Target: CD7-specific CAR gene-engineered T cells
Sponsor: Shenzhen Geno-Immune Medical Institute
Source URL: ClinicalTrials.gov
Source updated: Detailed source ingestion pending
Ingested: Jul 23, 2026
Model: trialsignal-ai-v1
Validation: validated
Matched by target_normalized: CD7-specific CAR gene-engineered T cells
View original source fields
Condition raw: T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
Condition normalized: T-cell Acute Lymphoblastic Leukemia, T-cell Acute Lymphoblastic Lymphoma, Acute Myeloid Leukemia, NK Cell Lymphoma
Modality raw: cell therapy
Modality normalized: cell therapy
Target raw: CD7-specific CAR gene-engineered T cells
Target normalized: CD7-specific CAR gene-engineered T cells